Editas Medicine Q4 EPS $(0.23) Beats $(0.54) Estimate, Collaboration and R&D Revenue $60.05M Beat $7.94M Estimate. Cash And Equivalents $427.1M
Author: Benzinga Newsdesk | February 28, 2024 08:02am
Editas Medicine (NASDAQ:
EDIT) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.54) by 57.41 percent. This is a 73.86 percent increase over losses of $(0.88) per share from the same period last year. The company reported quarterly sales of $60.05 million which beat the analyst consensus estimate of $7.94 million by 656.30 percent. This is a 818.76 percent increase over sales of $6.54 million the same period last year.
Posted In: EDIT